Everest Medicines, Singapore’s EDDC Enter Global Licensing Agreement for COVID Oral Antivirals

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Singapore Seeking Pharmaceutical Tariff Concessions from US

The deputy prime minister and trade minister of Singapore,...

Merck to Acquire Verona for $10B, COPD Drug in Focus

Merck has pulled off another acquisition that happens to...

PDUFA Crucial for Biopharmaceutical Innovation in the US

The United States happens to lead the world when...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Everest Medicines and Singapore’s Experimental Drug Development Centre (EDDC) entered a global licensing agreement under which Everest will obtain exclusive worldwide rights to develop, manufacture and commercialize EDDC’s series of viral 3C-like (3CL) protease inhibitors as potentially best-in-class COVID-19 oral antiviral treatments. EDDC is Singapore’s national platform for drug discovery and development and is hosted by the Agency for Science, Technology and Research (A*STAR).

Under the agreement, Everest obtains exclusive global rights to EDDC’s series of 3CL protease inhibitors that have demonstrated potent in-vitro activity against sar -CoV-2 and its variants, as well as other coronaviruses such as MERS. Everest has full rights to sub-license the drug further and will receive full technology transfer .

Under the terms of the transaction, EDDC will receive an initial upfront payment and downstream clinical and commercial milestone payments, as well as typical royalties on net sales of products.

The lead compound is EDDC-2214, a novel and potent SARS-CoV-2 3CL protease inhibitor, which Everest will develop as an oral antiviral COVID-19 therapy. The main protease in SARS-CoV-2 is the 3CL protease. Compared to several other oral COVID-19 antivirals, EDDC-2214 exhibits better in-vitro potency and preclinical oral bioavailability . Clinical trials evaluating EDDC-2214 are expected to begin later this year.

“EDDC-2214 and future potential 3CL protease inhibitors are impactful new assets that complement our existing COVID-19 vaccine program,” said Kerry Blanchard, MD, PhD, Chief Executive Officer of Everest Medicines. “We want to offer a package against COVID-19 that has both preventative vaccines and conveniently administered infection treatments. This is a prime example of the innovative risk-sharing relationship Everest is bringing about globally. We intend to bring the drug candidate quickly and efficiently through clinical trials, in order to deliver this novel oral antiviral treatment to patients during this time of limited therapeutic options.”

 

Latest stories

Related stories

Singapore Seeking Pharmaceutical Tariff Concessions from US

The deputy prime minister and trade minister of Singapore,...

Merck to Acquire Verona for $10B, COPD Drug in Focus

Merck has pulled off another acquisition that happens to...

PDUFA Crucial for Biopharmaceutical Innovation in the US

The United States happens to lead the world when...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back